Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/29023
Title: The effect of denosumab and alendronate on trabecular plate and rod microstructure at the distal tibia and radius: A post-hoc HR-pQCT study.
Austin Authors: Hu, Yizhong Jenny;Chines, Arkadi;Shi, Yifei;Seeman, Ego ;Guo, X Edward
Affiliation: Mary MacKillop Institute of Healthy Aging, Australian Catholic University, Melbourne, Australia..
Amgen Inc., Thousand Oaks, CA, USA..
Bone Bioengineering Laboratory, Department of Biomedical Engineering, Columbia University, New York, NY, USA..
Endocrinology
Medicine (University of Melbourne)
Issue Date: Jan-2022
Date: 2021
Publication information: Bone 2022; 154: 116187
Abstract: Age-related trabecular microstructural deterioration and conversion from plate-like trabeculae to rod-like trabeculae occur because of unbalanced rapid remodeling. As denosumab achieves greater remodeling suppression and lower cortical porosity than alendronate, we hypothesized that denosumab might also preserve trabecular plate microstructure, bone stiffness and strength more effectively than alendronate. In this post hoc analysis of a phase 2 study, postmenopausal women randomized to placebo (P, n = 74), denosumab (D, n = 72), or alendronate (A, n = 68). HR-pQCT scans of the distal radius and tibia were performed at baseline and Month-12 (M12). Trabecular compartment was subjected to Individual Trabecula Segmentation while finite element analysis was performed to estimate stiffness and strength. Percent change from baseline at M12 of each parameter was compared between patient groups. At the distal tibia, in the placebo group, plate surface area (pTb.S, -1.3%) decreased while rod bone volume fraction (rBV/TV, +4.5%) and number (rTb.N, +2.1%) increased. These changes were prevented by denosumab but persisted despite alendronate therapy (pTb.S: -1.7%; rBV/TV: +6.9%; rTb.N: +3.0%). Both treatments improved whole bone stiffness (D: +3.1%; A: +1.8%) and failure load (D: +3.0%; A: +2.2%); improvements using denosumab was significant compared to placebo (stiffness: p = 0.004; failure load: p = 0.003). At the distal radius, denosumab increased total trabecular bone volume fraction (BV/TV, +3.4%) and whole bone failure load (+4.0%), significantly different from placebo (BV/TV: p = 0.044; failure load: p = 0.046). Significantly different effects of either drug on plate and rod microstructure were not detected. Denosumab preserved trabecular plate microstructure. Alendronate did not. However, estimated strength did not differ between denosumab and alendronate treated groups.
URI: https://ahro.austin.org.au/austinjspui/handle/1/29023
DOI: 10.1016/j.bone.2021.116187
ORCID: 0000-0002-9692-048X
Journal: Bone
PubMed URL: 34530172
PubMed URL: https://pubmed.ncbi.nlm.nih.gov/34530172/
Type: Journal Article
Subjects: Antiresorptives
Bone QCT/microCT
Individual trabecula segmentation
Matrix mineralization
Microstructure
Osteoporosis
Appears in Collections:Journal articles

Show full item record

Page view(s)

52
checked on Dec 24, 2024

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.